Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.

Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, Künkele A.

Oncotarget. 2017 Apr 25;8(17):27882-27891. doi: 10.18632/oncotarget.15840.

2.

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.

Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH.

Oncotarget. 2017 Jan 24;8(4):6730-6741. doi: 10.18632/oncotarget.14268.

3.

MiR-34a deficiency accelerates medulloblastoma formation in vivo.

Thor T, Künkele A, Pajtler KW, Wefers AK, Stephan H, Mestdagh P, Heukamp L, Hartmann W, Vandesompele J, Sadowski N, Becker L, Garrett L, Hölter SM, Horsch M, Calzada-Wack J, Klein-Rodewald T, Racz I, Zimmer A, Beckers J, Neff F, Klopstock T, De Antonellis P, Zollo M, Wurst W, Fuchs H, Gailus-Durner V, Schüller U, de Angelis MH, Eggert A, Schramm A, Schulte JH.

Int J Cancer. 2015 May 15;136(10):2293-303. doi: 10.1002/ijc.29294. Epub 2014 Nov 25.

4.

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.

Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH.

Oncogene. 2015 Jun;34(26):3357-68. doi: 10.1038/onc.2014.269. Epub 2014 Sep 1.

5.

The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.

Pajtler KW, Weingarten C, Thor T, Künkele A, Heukamp LC, Büttner R, Suzuki T, Miyata N, Grotzer M, Rieb A, Sprüssel A, Eggert A, Schramm A, Schulte JH.

Acta Neuropathol Commun. 2013 May 29;1:19. doi: 10.1186/2051-5960-1-19.

6.

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.

Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, Sure U, Fleischhack G, Eggert A, Schulte JH.

Oncotarget. 2013 Nov;4(11):2080-95.

7.

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH.

Nat Genet. 2012 Nov;44(11):1199-206. doi: 10.1038/ng.2436. Epub 2012 Oct 7.

PMID:
23042116
8.

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, Pattyn F, Mestdagh P, Menten B, Kuhfittig-Kulle S, Künkele A, König K, Meder L, Chatterjee S, Ullrich RT, Schulte S, Vandesompele J, Speleman F, Büttner R, Eggert A, Schulte JH.

Sci Transl Med. 2012 Jul 4;4(141):141ra91. doi: 10.1126/scitranslmed.3003967.

9.

Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation.

Sprüssel A, Schulte JH, Weber S, Necke M, Händschke K, Thor T, Pajtler KW, Schramm A, König K, Diehl L, Mestdagh P, Vandesompele J, Speleman F, Jastrow H, Heukamp LC, Schüle R, Dührsen U, Buettner R, Eggert A, Göthert JR.

Leukemia. 2012 Sep;26(9):2039-51. doi: 10.1038/leu.2012.157. Epub 2012 Jun 13.

PMID:
22699452
10.

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Künkele A, De Preter K, Heukamp L, Thor T, Pajtler KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE, Speleman F, Schramm A, Eggert A, Schulte JH.

Neuro Oncol. 2012 Jul;14(7):859-69. doi: 10.1093/neuonc/nos115. Epub 2012 May 16.

11.

MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.

Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, Heukamp L, Schulte S, Molenaar J, Versteeg R, Thor T, Künkele A, Vandesompele J, Speleman F, Schorle H, Eggert A, Schramm A.

Oncogene. 2013 Feb 21;32(8):1059-65. doi: 10.1038/onc.2012.106. Epub 2012 Apr 9.

PMID:
22484425
12.

Accurate prediction of neuroblastoma outcome based on miRNA expression profiles.

Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S, Vermeulen J, Brockmeyer B, Pajtler K, Thor T, de Preter K, Speleman F, Morik K, Eggert A, Vandesompele J, Schramm A.

Int J Cancer. 2010 Nov 15;127(10):2374-85. doi: 10.1002/ijc.25436.

13.

Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma.

Schulte JH, Marschall T, Martin M, Rosenstiel P, Mestdagh P, Schlierf S, Thor T, Vandesompele J, Eggert A, Schreiber S, Rahmann S, Schramm A.

Nucleic Acids Res. 2010 Sep;38(17):5919-28. doi: 10.1093/nar/gkq342. Epub 2010 May 13.

14.
15.

[Spri strikes out at employers: poor planning behind many personnel problems].

Thor T.

Vardfacket. 1978 Apr 27;2(8):57-8. Swedish. No abstract available.

PMID:
247878
16.

[How to plan, administer and run health care (services) in the best way?].

Birke G, Thor T.

Lakartidningen. 1974 Feb 13;71(7):591-3. Swedish. No abstract available.

PMID:
4209561

Supplemental Content

Support Center